The clinical utility of Trial 1 of the Test of Memory Malingering (TOMM) has recently become a topic of investigation. The current study cross-validated previous research suggesting that those participants who score 45 or greater on Trial 1 of the TOMM will continue to do so on Trial 2 and the Retention Trial and extended these findings to broader clinical and nonclinical populations. Two archival samples were included for analyses: one sample of healthy community-dwelling elders and another sample drawn from an outpatient neuropsychology clinic. As demonstrated previously, 100% of those patients that scored 45 or greater on TOMM Trial 1 scored above cut-scores on Trial 2 and the Retention Trial, supporting the utility of a possible discontinuation rule on Trial 1. When combined with previous research, the current results provide further support for the clinical utility of Trial 1 in predicting overall performance on the TOMM; however, use of any nonstandard administration of the TOMM may not satisfy Daubert criteria in forensic settings and may not be appropriate.
- Test of Memory Malingering (TOMM)